Diagnostic classification of irritability and oppositionality in youth: a global field study comparing ICD-11 with ICD-10 and DSM-5 / Spencer C. EVANS in Journal of Child Psychology and Psychiatry, 62-3 (March 2021)  

Public ISBD [article]  inJournal of Child Psychology and Psychiatry > 62-3 (March 2021) . - p.303-312 Titre : Diagnostic classification of irritability and oppositionality in youth: a global field study comparing ICD-11 with ICD-10 and DSM-5 Type de document : Texte imprimé et/ou numérique Auteurs : Spencer C. EVANS, Auteur ; Michael C. ROBERTS, Auteur ; Jared W. KEELEY, Auteur ; Tahilia J. REBELLO, Auteur ; Francisco DE LA PEÑA, Auteur ; John E. LOCHMAN, Auteur ; Jeffrey D. BURKE, Auteur ; Paula J. FITE, Auteur ; Lourdes EZPELETA, Auteur ; Walter MATTHYS, Auteur ; Eric A. YOUNGSTROM, Auteur ; Chihiro MATSUMOTO, Auteur ; Howard F. ANDREWS, Auteur ; María ELENA MEDINA-MORA, Auteur ; José L. AYUSO-MATEOS, Auteur ; Brigitte KHOURY, Auteur ; Mayya KULYGINA, Auteur ; Rebeca ROBLES, Auteur ; Pratap SHARAN, Auteur ; Min ZHAO, Auteur ; Geoffrey M. REED, Auteur Article en page(s) : p.303-312 Langues : Anglais (eng) Mots-clés : International Classification of Diseases (ICD-11)  child and adolescent mental health  irritability  mood dysregulation  oppositional defiant disorder Index. décimale : PER Périodiques Résumé : BACKGROUND: Severe irritability has become an important topic in child and adolescent mental health. Based on the available evidence and on public health considerations, WHO classified chronic irritability within oppositional defiant disorder (ODD) in ICD-11, a solution markedly different from DSM-5's (i.e. the new childhood mood diagnosis, disruptive mood dysregulation disorder [DMDD]) and from ICD-10's (i.e. ODD as one of several conduct disorders without attention to irritability). In this study, we tested the accuracy with which a global, multilingual, multidisciplinary sample of clinicians were able to use the ICD-11 classification of chronic irritability and oppositionality as compared to the ICD-10 and DSM-5 approaches. METHODS: Clinicians (N = 196) from 48 countries participated in an Internet-based field study in English, Spanish, or Japanese and were randomized to review and use one of the three diagnostic systems. Through experimental manipulation of validated clinical vignettes, we evaluated how well clinicians in each condition could identify chronic irritability versus nonirritable oppositionality, episodic bipolar disorder, dysthymic depression, and normative irritability. RESULTS: Compared to ICD-10 and DSM-5, ICD-11 led to more accurate identification of severe irritability and better differentiation from boundary presentations. Participants using DSM-5 largely failed to apply the DMDD diagnosis when it was appropriate, and they more often applied psychopathological diagnoses to developmentally normative irritability. CONCLUSIONS: The formulation of irritability and oppositionality put forth in ICD-11 shows evidence of clinical utility, supporting accurate diagnosis. Global mental health clinicians can readily identify ODD both with and without chronic irritability. En ligne : http://dx.doi.org/10.1111/jcpp.13244 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=443 [article] Diagnostic classification of irritability and oppositionality in youth: a global field study comparing ICD-11 with ICD-10 and DSM-5 [Texte imprimé et/ou numérique] / Spencer C. EVANS, Auteur ; Michael C. ROBERTS, Auteur ; Jared W. KEELEY, Auteur ; Tahilia J. REBELLO, Auteur ; Francisco DE LA PEÑA, Auteur ; John E. LOCHMAN, Auteur ; Jeffrey D. BURKE, Auteur ; Paula J. FITE, Auteur ; Lourdes EZPELETA, Auteur ; Walter MATTHYS, Auteur ; Eric A. YOUNGSTROM, Auteur ; Chihiro MATSUMOTO, Auteur ; Howard F. ANDREWS, Auteur ; María ELENA MEDINA-MORA, Auteur ; José L. AYUSO-MATEOS, Auteur ; Brigitte KHOURY, Auteur ; Mayya KULYGINA, Auteur ; Rebeca ROBLES, Auteur ; Pratap SHARAN, Auteur ; Min ZHAO, Auteur ; Geoffrey M. REED, Auteur . - p.303-312. Langues : Anglais (eng) in Journal of Child Psychology and Psychiatry > 62-3 (March 2021) . - p.303-312 Mots-clés : International Classification of Diseases (ICD-11)  child and adolescent mental health  irritability  mood dysregulation  oppositional defiant disorder Index. décimale : PER Périodiques Résumé : BACKGROUND: Severe irritability has become an important topic in child and adolescent mental health. Based on the available evidence and on public health considerations, WHO classified chronic irritability within oppositional defiant disorder (ODD) in ICD-11, a solution markedly different from DSM-5's (i.e. the new childhood mood diagnosis, disruptive mood dysregulation disorder [DMDD]) and from ICD-10's (i.e. ODD as one of several conduct disorders without attention to irritability). In this study, we tested the accuracy with which a global, multilingual, multidisciplinary sample of clinicians were able to use the ICD-11 classification of chronic irritability and oppositionality as compared to the ICD-10 and DSM-5 approaches. METHODS: Clinicians (N = 196) from 48 countries participated in an Internet-based field study in English, Spanish, or Japanese and were randomized to review and use one of the three diagnostic systems. Through experimental manipulation of validated clinical vignettes, we evaluated how well clinicians in each condition could identify chronic irritability versus nonirritable oppositionality, episodic bipolar disorder, dysthymic depression, and normative irritability. RESULTS: Compared to ICD-10 and DSM-5, ICD-11 led to more accurate identification of severe irritability and better differentiation from boundary presentations. Participants using DSM-5 largely failed to apply the DMDD diagnosis when it was appropriate, and they more often applied psychopathological diagnoses to developmentally normative irritability. CONCLUSIONS: The formulation of irritability and oppositionality put forth in ICD-11 shows evidence of clinical utility, supporting accurate diagnosis. Global mental health clinicians can readily identify ODD both with and without chronic irritability. En ligne : http://dx.doi.org/10.1111/jcpp.13244 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=443

A methylation study implicates the rewiring of brain neural circuits during puberty in the emergence of sex differences in depression symptoms / Robin F. CHAN in Journal of Child Psychology and Psychiatry, 63-7 (July 2022)  

Public ISBD [article]  inJournal of Child Psychology and Psychiatry > 63-7 (July 2022) . - p.802-809 Titre : A methylation study implicates the rewiring of brain neural circuits during puberty in the emergence of sex differences in depression symptoms Type de document : Texte imprimé et/ou numérique Auteurs : Robin F. CHAN, Auteur ; William E. COPELAND, Auteur ; Min ZHAO, Auteur ; Lin Y. XIE, Auteur ; Jane COSTELLO, Auteur ; Karolina A. ABERG, Auteur ; Edwin J. C. G. VAN DEN OORD, Auteur Article en page(s) : p.802-809 Langues : Anglais (eng) Mots-clés : Brain  DNA Methylation  Depression/genetics  Female  Genome-Wide Association Study  Humans  Male  Puberty  Sex Characteristics  Affective disorders  biomarkers  epigenetics  sex differences Index. décimale : PER Périodiques Résumé : BACKGROUND: Women are 1.5-3 times more likely to suffer from depression than men. This sex bias first emerges during puberty and then persists across the reproductive years. As the cause remains largely elusive, we performed a methylation-wide association study (MWAS) to generate novel hypotheses. METHODS: We assayed nearly all 28 million possible methylation sites in blood in 595 blood samples from 487 participants aged 9-17. MWASs were performed to identify methylation sites associated with increasing sex differences in depression symptoms as a function of pubertal stage. Epigenetic deconvolution was applied to perform analyses on a cell-type specific level. RESULTS: In monocytes, a substantial number of significant associations were detected after controlling the FDR at 0.05. These results could not be explained by plasma testosterone/estradiol or current/lifetime trauma. Our top results in monocytes were significantly enriched (ratio of 2.48) for genes in the top of a large genome-wide association study (GWAS) meta-analysis of depression and neurodevelopment-related Gene Ontology (GO) terms that remained significant after correcting for multiple testing. Focusing on our most robust findings (70 genes overlapping with the GWAS meta-analysis and the significant GO terms), we find genes coding for members of each of the major classes of axon guidance molecules (netrins, slits, semaphorins, ephrins, and cell adhesion molecules). Many of these genes were previously implicated in rodent studies of brain development and depression-like phenotypes, as well as human methylation, gene expression and GWAS studies. CONCLUSIONS: Our study suggests that the emergence of sex differences in depression may be related to the differential rewiring of brain circuits between boys and girls during puberty. En ligne : http://dx.doi.org/10.1111/jcpp.13522 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=477 [article] A methylation study implicates the rewiring of brain neural circuits during puberty in the emergence of sex differences in depression symptoms [Texte imprimé et/ou numérique] / Robin F. CHAN, Auteur ; William E. COPELAND, Auteur ; Min ZHAO, Auteur ; Lin Y. XIE, Auteur ; Jane COSTELLO, Auteur ; Karolina A. ABERG, Auteur ; Edwin J. C. G. VAN DEN OORD, Auteur . - p.802-809. Langues : Anglais (eng) in Journal of Child Psychology and Psychiatry > 63-7 (July 2022) . - p.802-809 Mots-clés : Brain  DNA Methylation  Depression/genetics  Female  Genome-Wide Association Study  Humans  Male  Puberty  Sex Characteristics  Affective disorders  biomarkers  epigenetics  sex differences Index. décimale : PER Périodiques Résumé : BACKGROUND: Women are 1.5-3 times more likely to suffer from depression than men. This sex bias first emerges during puberty and then persists across the reproductive years. As the cause remains largely elusive, we performed a methylation-wide association study (MWAS) to generate novel hypotheses. METHODS: We assayed nearly all 28 million possible methylation sites in blood in 595 blood samples from 487 participants aged 9-17. MWASs were performed to identify methylation sites associated with increasing sex differences in depression symptoms as a function of pubertal stage. Epigenetic deconvolution was applied to perform analyses on a cell-type specific level. RESULTS: In monocytes, a substantial number of significant associations were detected after controlling the FDR at 0.05. These results could not be explained by plasma testosterone/estradiol or current/lifetime trauma. Our top results in monocytes were significantly enriched (ratio of 2.48) for genes in the top of a large genome-wide association study (GWAS) meta-analysis of depression and neurodevelopment-related Gene Ontology (GO) terms that remained significant after correcting for multiple testing. Focusing on our most robust findings (70 genes overlapping with the GWAS meta-analysis and the significant GO terms), we find genes coding for members of each of the major classes of axon guidance molecules (netrins, slits, semaphorins, ephrins, and cell adhesion molecules). Many of these genes were previously implicated in rodent studies of brain development and depression-like phenotypes, as well as human methylation, gene expression and GWAS studies. CONCLUSIONS: Our study suggests that the emergence of sex differences in depression may be related to the differential rewiring of brain circuits between boys and girls during puberty. En ligne : http://dx.doi.org/10.1111/jcpp.13522 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=477

A proprietary herbal medicine (5-Ling Granule) for Tourette syndrome: a randomized controlled trial / Yi ZHENG in Journal of Child Psychology and Psychiatry, 57-1 (January 2016)  

Public ISBD [article]  inJournal of Child Psychology and Psychiatry > 57-1 (January 2016) . - p.74-83 Titre : A proprietary herbal medicine (5-Ling Granule) for Tourette syndrome: a randomized controlled trial Type de document : Texte imprimé et/ou numérique Auteurs : Yi ZHENG, Auteur ; Zhang-Jin ZHANG, Auteur ; Xin-Min HAN, Auteur ; Ying DING, Auteur ; Yu-Yan CHEN, Auteur ; Xue-Feng WANG, Auteur ; Xiao-Wei WEI, Auteur ; Min-Jie WANG, Auteur ; Yan CHENG, Auteur ; Zhao-Hong NIE, Auteur ; Min ZHAO, Auteur ; Xi-Xi ZHENG, Auteur Article en page(s) : p.74-83 Langues : Anglais (eng) Mots-clés : Tourette syndrome  tics  herbal medicine  tiapride  5-Ling Granule Index. décimale : PER Périodiques Résumé : Background Tourette syndrome (TS) is a common tic disorder in children and adolescents. There is preliminary evidence that herbal medicine may possess the potential to treat tics. The purpose of this study was to formally evaluate the efficacy and safety of 5-Ling Granule (5-LGr), a proprietary polyherbal product, for the treatment of patients with TS in comparison with tiapride and placebo. Methods In this multisite, double-blind, double-dummy, randomized, placebo-controlled trial, 603 patients with TS aged 5–18 years were randomly assigned to treatment with placebo (n = 117), tiapride (n = 123, 200–400 mg/day) or 5-LGr (n = 363, 15–22.5 g/day) for 8 weeks. The primary outcome was measured using the Yale Global Tic Severity Scale (YGTSS) and its subscales, total tic Score (TTS) and tic-related impairment. Incidence of adverse events was compared among the three groups. Results While tics of all patients were reduced over time, 5-LGr and tiapride treatment produced significantly greater improvement on the YGTSS overall scale and subscale for TTS and impairment at endpoint than the placebo. Seventy-four percentage of patients in the 5-LGr arm and 68.3% in the tiapride arm had clinical response and these rates of response were significantly higher than those on placebo (44.0%, p < .001). The incidence of overall adverse events was significantly fewer for patients on placebo and 5-LGr compared to tiapride (11.2% and 13.8% vs. 26.0%, p = .002); in particular physical tiredness, dizziness and sleep disturbance. Conclusions The clinical efficacy of 5-LGr is comparable to tiapride in reducing tics. Its safety profile is better than tiapride. 5-LGr can be considered a safe and effective therapy for TS (Trial registration: www.clinicaltrials.gov: NCT01501695). En ligne : http://dx.doi.org/10.1111/jcpp.12432 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=273 [article] A proprietary herbal medicine (5-Ling Granule) for Tourette syndrome: a randomized controlled trial [Texte imprimé et/ou numérique] / Yi ZHENG, Auteur ; Zhang-Jin ZHANG, Auteur ; Xin-Min HAN, Auteur ; Ying DING, Auteur ; Yu-Yan CHEN, Auteur ; Xue-Feng WANG, Auteur ; Xiao-Wei WEI, Auteur ; Min-Jie WANG, Auteur ; Yan CHENG, Auteur ; Zhao-Hong NIE, Auteur ; Min ZHAO, Auteur ; Xi-Xi ZHENG, Auteur . - p.74-83. Langues : Anglais (eng) in Journal of Child Psychology and Psychiatry > 57-1 (January 2016) . - p.74-83 Mots-clés : Tourette syndrome  tics  herbal medicine  tiapride  5-Ling Granule Index. décimale : PER Périodiques Résumé : Background Tourette syndrome (TS) is a common tic disorder in children and adolescents. There is preliminary evidence that herbal medicine may possess the potential to treat tics. The purpose of this study was to formally evaluate the efficacy and safety of 5-Ling Granule (5-LGr), a proprietary polyherbal product, for the treatment of patients with TS in comparison with tiapride and placebo. Methods In this multisite, double-blind, double-dummy, randomized, placebo-controlled trial, 603 patients with TS aged 5–18 years were randomly assigned to treatment with placebo (n = 117), tiapride (n = 123, 200–400 mg/day) or 5-LGr (n = 363, 15–22.5 g/day) for 8 weeks. The primary outcome was measured using the Yale Global Tic Severity Scale (YGTSS) and its subscales, total tic Score (TTS) and tic-related impairment. Incidence of adverse events was compared among the three groups. Results While tics of all patients were reduced over time, 5-LGr and tiapride treatment produced significantly greater improvement on the YGTSS overall scale and subscale for TTS and impairment at endpoint than the placebo. Seventy-four percentage of patients in the 5-LGr arm and 68.3% in the tiapride arm had clinical response and these rates of response were significantly higher than those on placebo (44.0%, p < .001). The incidence of overall adverse events was significantly fewer for patients on placebo and 5-LGr compared to tiapride (11.2% and 13.8% vs. 26.0%, p = .002); in particular physical tiredness, dizziness and sleep disturbance. Conclusions The clinical efficacy of 5-LGr is comparable to tiapride in reducing tics. Its safety profile is better than tiapride. 5-LGr can be considered a safe and effective therapy for TS (Trial registration: www.clinicaltrials.gov: NCT01501695). En ligne : http://dx.doi.org/10.1111/jcpp.12432 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=273

---

1 (1 - 3 / 3)